Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
38 results about "Retrovirus Infections" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Compositions and methods for treating retrovirus infections
ActiveUS20120053223A1Inhibit expressionMaximizing numberOrganic active ingredientsGenetic material ingredientsNucleotideViral infection
The present invention relates to at least one nucleic acid (i) comprising or consisting of or (ii) encoding a nucleic acid comprising or consisting of, a sequence selected from the group consisting of: 1) SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and 2) a sequence derived from SEQ ID NO: 1 to 4 by substitution deletion or insertion of at least one nucleotide, provided that a nucleic acid consisting of the sequence derived from SEQ ID NO: 1 to 4 is liable to induce HIV-1 expression in latent HIV-1-infected cells, for use as a medicament, in particular for treating retrovirus infections.
Owner:CENT NAT DE LA RECHERCHE SCI
Use of tailored recombinases for the treatment of retroviral infections
The present invention is directed to a method for preparing an expression vector encoding a tailored recombinase, wherein said tailored recombinase recombines asymmetric target sites within the LTR of proviral DNA of a retrovirus inserted into the genome of a host cell and is useful as means for excising the provirus from the genome of the host cell. The present invention further relates to an in vitro-method of optimising the treatment of a retroviral infection of a subject and to the use of tailored recombinases for the preparation of pharmaceutical compositions for reducing the viral load in a subjected infected by a retrovirus.
Owner:DRESDEN UNIVERSITY OF TECHNOLOGY +2
Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
The present invention provides a use of a therapeutically effective amount of 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (herein referred to as Compound I) or a pharmaceutically acceptable salt thereof, for the production of an agent for the treatment in a patient. The invention further provides a use of Compound I or a salt thereof for an agent for inhibition of integrase activity. Compound I or a salt thereof is also effective in inhibiting the replication of a retrovirus resistant to at least one anti-retroviral drug. In the use of the invention, Compound I or a salt thereof may be administered alone or in combination with at least one anti-retroviral drug other than Compound I or a salt thereof. The present invention also provides kits comprising Compound I or a salt thereof.
![Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/611600dc-1211-4e60-800c-801fe638b18a/US20090018162A1-20090115-C00001.png "Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection")
![Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/611600dc-1211-4e60-800c-801fe638b18a/US20090018162A1-20090115-C00002.png "Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection")
Owner:JAPAN TOBACCO INC
Retroviral immunotherapy
InactiveUS20090041760A1Limited abilityEffectively control or eradicate the retroviral infectionBiocideOrganic active ingredientsMammalRetroviral infection
The present inventor has noted that at least two populations of immune cells are produced in response to retroviruses which infect mammals. More particularly, the immune system of a mammal infected with a retrovirus is capable of mounting an immune response against the virus through a group of cells herein generally referred to as “effector cells”, however, a second population of cells are also produced which regulate the “effector cells”, herein generally referred to as “regulator cells” (or suppressor cells), limiting the mammal's ability to effectively control or eradicate the retroviral infection. Accordingly, the present invention utilizes these observations to provide methods for treating a mammal with a retroviral infection.
Owner:BIOTEMPUS PTY LTD
Direct and biochemically functional detection process of retrovirus in biological samples
InactiveUS6268123B1Microbiological testing/measurementEnzymologyRetroviral infectionEnzyme catalysis
The present invention relates to processes for the direct detection of biochemically functional retroviruses in biological samples. The processes of the invention are characterized by the structure-specific extraction of retrovirus particles and a subsequent analysis and detection of retrovirus-specific enzymatic reactions. The processes of the invention have broad application in the diagnosis of retroviral infection and virological research.
Owner:RETRO TECH
Vaccine
InactiveUS20150174235A1Good effectReducing and delaying risk of developing and pathological effectOrganic active ingredientsViral antigen ingredientsActive agentImmunomodulations
The present invention relates to novel combinations of active agents and methods for treatment of retrovirus infections including HIV infections and AIDS. In particular, the present invention relates to novel use of administrations and combinations of a compound to stimulate the humoral immunity and / or peptides that elicit a cell-mediated immune response in a subject; and immunomodulatory compounds and / or a reservoir purging agent, such as a histone deacetylase (HDAC) inhibitor.
Owner:BIONOR IMMUNO
A new quinoline derivative for use in the treatment and prevention of viral infections
The present invention relates to a quinoline derivative of formula (1) or one of its pharmaceutically acceptable salts. The present invention further relates to said quinoline derivative for medicament and for use in the treatment or prevention of a viral or retroviral infection and in particular AIDS or an AIDS-related condition or Human Immunodeficiency virus (HIV). The present invention also relates to a pharmaceutical composition comprising said quinoline derivative and to the process for preparing it as to a novel intermediate compound.
Owner:ABIVAX +3
Pyrrolopyridazine compounds with antiviral properties
The invention discloses pyrrolopyridazine compounds used for treating or preventing HIV (human immunodeficiency virus) infection or other virus infections. The compounds can be used for as inhibitors for inhibiting HIV replication and can be used with other treatment drugs (particularly other antiviral drugs). Specifically, the invention discloses compounds for inhibiting HIV replication, a drug containing the compounds and a method for treating retrovirus infection through the compounds, for example, HIV infection. More specifically, the invention discloses an integrase allosteric inhibitor.
Owner:世方科技(杭州)有限公司
Mouse model of acute lymphoblastic leukemia and modeling method
ActiveCN106520805ASimplify the modeling processReduce the risk of accidental deathBlood/immune system cellsFermentationHematopoietic cellAcute lymphocytic leukemia
The invention provides a mouse model of acute lymphoblastic leukemia and a modeling method, and relates to the field of biotechnology. The preparation method comprises the following steps: infecting IL-7 stimulated hematopoietic cells with retroviruses with BCR-ABLP190; and transfusing the stimulated hematopoietic cells to syngenic mice. The method has the advantages of being simple and easy to implement in a modeling process and capable of establishing the ph+ALL mouse model in one step. According to the mouse model of the acute lymphoblastic leukemia provided by the invention, the sorted BCR-ABL+B cells are transfused to the syngenic mice for the second time without irradiation treatment, with performance consistent with that of mice of first episode; the model is good in stability; and in addition, the uniformity of recipient mice is enhanced and such risks as accidental death of the recipient mice due to irradiation are reduced.
Owner:XUZHOU MEDICAL UNIV
Antiretroviral pyridine and quinoline derivatives
Certain pyridine and quinoline derivatives which inhibit replication of the retroviruses HIV-1, HIV-2 and human cytomegalovirus (HCMV) are provided. Pharmaceutical compositions useful in methods of treating or inhibiting certain retrovirus infections are described.
Owner:UNIROYAL CHEM CO INC
Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
Selected sulfonylalkanoylamino hydroxyethylamine sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.
Owner:GD SEARLE & CO
Biological models capable of exhibiting secondary disease manifestations and useful for developing therapeutic drugs, diagnostic products and therapeutic or diagnostic procedures, methods of using same, and cells, tissues and organs derived therefrom
This invention provides novel animal models for a human pathogen that is capable of exhibiting analogous secondary disease manifestation. Other animal models for a human pathogen are provided by this invention which are capable of exhibiting analogous secondary disease manifestations and are also capable of responding to therapeutic or preventive measures to such secondary disease manifestations. Other animal models for human retrovirus infections are provided including lower primates and primate excluding any members of the order Anthropoidea. Compositions, drugs, products and procedures for therapeutic and diagnostic applications derived from the animal models of this invention are also described and provided.
Owner:ENZO THERAPEUTICS
Tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains
InactiveUS20130164271A1Simple definitionReduce poolingBiocideBacteriaProviral dnaLong terminal repeat
The present invention relates to a method for preparing an expression vector encoding a tailored recombinase, which tailored recombinase is capable of recombining asymmetric target sequences within the long terminal repeat (LTR) of proviral DNA of a plurality of retrovirus strains inserted into the genome of a host cell, as well as to the obtained expression vector, cells transfected with this, expressed recombinase and pharmaceutical compositions comprising the expression vector, cells and / or recombinase. Pharmaceutical compositions are useful, e.g., in treatment and / or prevention of retrovirus infection. In particular, asymmetric target sequences present in a plurality of HIV strains are disclosed, as well as tailored recombinases capable of combining these sequences (Tre 3.0 and 4.0) and expression vectors encoding them.
Owner:HEINRICH PETTE INST LEIBNIZ INST FUR EXPERIMENTELLE VIROLOGIE STIFTUNG BURGERLICHEN RECHTS +1
Tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains
ActiveUS20170130212A1Simple definitionReduce poolingHydrolasesPeptide/protein ingredientsProviral dnaLong terminal repeat
Owner:LEIBNIZ-INST FUR VIROLOGIE
Intergrase inhibitor
The invention relates to an intergrase inhibitor, and discloses compounds for treating or preventing HIV infection or other virus infections. The compounds can be used as an HIV replication inhibitor, and can be used together with other treatment medicines, especially other antiviral medicines. The invention concretely discloses the compounds for inhibiting HIV replication, medicines containing the compounds, and methods for treating retroviral infection, such as HIV infection through using the compounds, and also discloses an intergrase allosteric inhibitor.
Owner:世方科技(杭州)有限公司
Compositions and methods for treating retrovirus infections
ActiveUS9439923B2Maximizing numberOrganic active ingredientsAntiviralsNucleotideRetrovirus Infections
The present invention relates to at least one nucleic acid (i) comprising or consisting of or (ii) encoding a nucleic acid comprising or consisting of, a sequence selected from the group consisting of: 1) SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and 2) a sequence derived from SEQ ID NO: 1 to 4 by substitution deletion or insertion of at least one nucleotide, provided that a nucleic acid consisting of the sequence derived from SEQ ID NO: 1 to 4 is liable to induce HIV-1 expression in latent HIV-1-infected cells, for use as a medicament, in particular for treating retrovirus infections.
Owner:CENT NAT DE LA RECHERCHE SCI
Compositions of lopinavir and ritonavir
ActiveUS9532979B2Optimize allocationPromote accumulationPowder deliveryOrganic active ingredientsRetroviral infectionPolyethylene glycol
The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drugs lopinavir and ritonavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and / or prevention of retroviral infections such as human immunodeficiency virus (HIV).
Owner:UNIV OF LIVERPOOL
Method for immortalizing myoblasts
PendingCN112646782AHigh yieldIncrease the proportionGenetically modified cellsSkeletal/connective tissue cellsBiotechnologyMyodystrophies
The invention discloses a method for immortalizing myoblasts. According to the method, low-density culture is adopted, retrovirus infection under the centrifugal condition is combined, improvement of repeated adherent enrichment immortal myoblasts is combined, operation conditions are optimized and controlled, the cell infection efficiency of the retroviruses is greatly improved, and the yield of the immortal myoblasts is greatly increased. According to the method, as for samples with very small initial sample size, particularly very low myoblast proportion (lower than 10% or even only 1%) in initial samples, immortalized myoblasts still can be successfully and permanently formed, and most samples can ensure that immortalized myoblasts with the purity of 70% or above can be finally obtained. According to the scheme, all muscular dystrophy patients can be benefited, and good application value and prospects are achieved.
Owner:广东赤萌医疗科技有限公司
Non-proteolysable oligopeptides that inhibit glycoprotein gp41 of the aids virus
InactiveUS20100197606A1Peptide/protein ingredientsInactivation/attenuationImmunodeficiency virusRetroviral infection
The invention relates to non-proteolysable oligopeptides that inhibit glycoprotein 41 of the AIDS virus. More specifically, the invention relates to the identification of oligopeptides, particularly hexapeptides, (D), (L) or mixed, preferably D-hexapeptides, which inhibit the binding of a retrovirus to a target cell, thereby providing novel therapies against infection from the human immunodeficiency virus (HIV). The invention also relates to the use of said D-hexapeptides in the form of single components or complex mixtures as prophylactic or therapeutic agents for retroviral infections, especially human immunodeficiency virus type 1 (HIV-1).
Owner:VASCO UNIV DEL PAIS +2
Tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains
Owner:HEINRICH PETTE INST LEIBNIZ INST FUR EXPE VIROLOGIE - STIFTUNG BUGERLICHEN RECHTS +1
Betaretrovirus epitopes and related methods of use
ActiveUS20200166511A1Organic active ingredientsPeptide/protein ingredientsEpitopeImmune effector cell
Methods for determination of risk, previous history and / or presence of a betaretrovirus infection in a subject are described herein. Said methods may comprise incubating a biological sample from the subject, the biological sample comprising immune effector-producing cells, with one or more betaretrovirus-specific epitopes, the betaretrovirus-specific epitopes comprising at least 7 contiguous amino acids according to any one of SEQ ID Nos. 1-36, and measuring the production of immune effectors by the immune effector-producing cells, wherein production of the immune effectors by the immune effector-producing cells determines risk and / or presence of betaretrovirus infection in the subject. Isolated peptides and kits for carrying out the methods are also described.
Owner:MASON ANDREW L +2
2-amino-9H-purin-9-yl compounds and methods for inhibiting/treating HIV infections and AIDS related symptoms
InactiveUS6900315B2Inhibit growth and elaboration and replicationRelieve symptomsBiocideSugar derivativesPhosphoric Acid EstersAcquired immunodeficiency
The present invention relates to novel compounds, compositions and methods for inhibiting the growth, elaboration and / or replication of HIV in human patients and to the prevention and treatment of human acquired immunodeficiency syndrome (AIDS) and other diseases caused by retroviral infection. More particularly, in preferred aspects, the present invention provides a method for the use of novel prodrug forms of 9-(2,3-Dideoxy-β-D-glycero-pent-2-enofuranosyl) guanine (d4G) for the prevention and treatment of both wild type and drug-resistant Human Immunodeficiency Virus (HIV), the causative pathogen of AIDS. Compounds according to the present invention are based upon the chemical formula: where X is OCH3, N3, NHCH3, N(CH3)2 or an aminocyclopropyl group;[0001]R1 is H or a C1 to C20 acyl or ether group, a phosphate, diphosphate, triphosphate or phosphodiester group; and[0002]R2 is H or a C1 to C20 acyl or alkyl group.
Owner:UNIV OF GEORGIA RES FOUND INC +1
Compositions and related methods for reconstituting the immune sytem of a subject
ActiveUS20200215105A1Maximize effectivenessPatient compliance is goodHeavy metal active ingredientsSulfonylurea active ingredientsImmunodeficiency virusSulfonylurea
Disclosed are pharmaceutical compositions and related methods for treating a subject with a viral or retroviral infection. The disclosed compositions and methods comprise and utilize an effective amount of one or more vanadium-containing compounds and an effective amount of one or more sulfonylureas. In certain embodiments, the viral infection is human immunodeficiency virus (HIV) and the compositions and methods improve one or more immunologic cellular parameters, such as viral load, CD4 counts and CD4 / CD8 lymphocyte cell ratios in a subject. Also disclosed are methods of improving one or more immunologic cellular parameters that are associated with viral infections such as HIV in a subject, including viral load, CD4 counts and CD4 / CD8 lymphocyte cell ratios.
Owner:GUTIERREZ ENRIQUE G
Hydrates of dolutegravir sodium
ActiveUS10189860B2Well formedImprove propertiesOrganic chemistry methodsAntiviralsRetroviral infectionDolutegravir sodium
The invention relates to novel hydrates of dolutegravir sodium and to processes for their preparation. Furthermore, the invention relates to a novel crystalline form of dolutegravir sodium, which is a useful intermediate for the preparation of one of the novel hydrates. In addition, the invention relates to the use of the novel hydrates for the production of pharmaceutical compositions. Finally, the invention relates to pharmaceutical compositions comprising an effective amount of the novel hydrates, to oral dosage forms comprising said pharmaceutical compositions, to a process for preparing said oral dosage forms, and to the use of said pharmaceutical compositions or dosage forms in the treatment of retroviral infections such as HIV-1 infections.
Owner:LEK PHARMA D D +1
Retrovirus-infection inhibitor
InactiveUS20100056629A1Low cytotoxicityBiocideOrganic chemistryImmunodeficiency virusActive ingredient
An infection inhibitor of retrovirus, particularly human immunodeficiency virus, comprising, as an active ingredient, at least one compound selected from the group consisting of a compound represented by the formula (I) (GGA) or a salt thereof, a compound represented by the formula (II) (NIK-333) or a salt thereof, and derivatives thereof.
Owner:NAGASAKI UNIVERSITY +1
Therapeutic or prophylactic agent for immunodeficiency virus infection
InactiveUS20160108122A1Reduce in quantityAntiviralsImmunoglobulins against cell receptors/antigens/surface-determinantsCXCR4Immunodeficiency virus
Disclosed is a novel means that enables complete cure of not only acute and chronic virus infections, but also latent retrovirus infections in which incorporation of the virus into the host chromosome has occurred. In the present invention, by destroying cells containing molecules that act as scaffolds for the virus infection in the patient's body, cells per se that have been already infected with virus are destroyed while inhibiting expansion of the virus infection in the patient's body, so that final complete cure of virus infection can be realized. The treatment of immunodeficiency virus infection may be carried out by administering an antibody or the like having high cytotoxic activity to the patient to destroy at least any of CD4 molecule-containing cells, CCR5 molecule-containing cells, and CXCR4 molecule-containing cells, preferably CD4 molecule-containing cells.
Owner:IDAC THERANOSTICS
Poxvirus Vector Encoding Retrovirus (Eg Hiv) And Cytokine
InactiveUS20080044377A1Easy maintenancePrevent and reduce delayPeptide/protein ingredientsViral antigen ingredientsCytokineViral antigens
In one embodiment, there is provided a method for treatment or prophylaxis of one or more symptoms of a retrovirus infection such as HIV infection, comprising the administration of poxvirus vector encoding a retrovirus antigen and a cytokine, or a functional homolog, derivative part or analog thereof, in conjunction with anti-retroviral drug therapy wherein said polypeptide and / or cytokine are expressed in a subject and are effective in maintaining a low viral load in a subject for a period of time, for example effectively preventing, reducing or delaying viral rebound during interruption of anti-retroviral drug treatment.
Owner:VIRAX DEV PTY LTD
Retroviral protease inhibitor combinations
InactiveUS20060240410A1Effective controlPeptide/protein ingredientsMicrobiological testing/measurementProteinase activityRetroviral protease inhibitor
The present invention is directed to a method for the treatment of mammalian retrovirus infections, such as HIV, using combinations of retroviral protease inhibitors which are effective in preventing the replication of the retroviruses in vitro or in vivo. This invention, in particular, relates to protease inhibitor compounds used in combination therapy with other protease inhibitor compounds. This invention also relates to combination therapy with a combination of protease inhibitors and antiviral agents other than protease inhibitors.
Owner:GD SEARLE & CO
Retrovirus-infection inhibitor
InactiveUS20120065263A1Low cytotoxicityBiocideHydroxy compound active ingredientsChemical compoundImmunodeficiency virus
An infection inhibitor of retrovirus, particularly human immunodeficiency virus, comprising, as an active ingredient, at least one compound selected from the group consisting of a compound represented by the formula (I) (GGA) or a salt thereof, a compound represented by the formula (II) (NIK-333) or a salt thereof, and derivatives thereof.
Owner:NAGASAKI UNIVERSITY +1
Compositions of lopinavir
ActiveUS10603279B2Advanced dosage formImprove distributionPowder deliveryOrganic active ingredientsHydrophilic polymersPolyvinyl alcohol
Owner:UNIV OF LIVERPOOL
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com